Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia
| Autor: | C. S. Carr, D R Knight, H Masamune, R J Hill, W R Tracey, Scott P. Kennedy, Derek M. Yellon |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Agonist
medicine.medical_specialty Adenosine Physiology medicine.drug_class Dipropylcyclopentylxanthine Myocardial Ischemia Myocardial Reperfusion In Vitro Techniques Models Biological chemistry.chemical_compound Adenosine A1 receptor Physiology (medical) Internal medicine Purinergic P1 Receptor Agonists medicine Humans Heart Atria Receptor business.industry Receptor Adenosine A3 Receptors Purinergic P1 Antagonist Myocardial Contraction Adenosine receptor Endocrinology Purinergic P1 Receptor Antagonists chemistry Xanthines Ischemic Preconditioning Myocardial Ischemic preconditioning Cardiology and Cardiovascular Medicine business Dinucleoside Phosphates medicine.drug |
| Zdroj: | Cardiovascular Research. 36:52-59 |
| ISSN: | 0008-6363 |
| DOI: | 10.1016/s0008-6363(97)00160-0 |
| Popis: | Objective: Adenosine receptor activation has been implicated in the mechanism of ischaemic preconditioning protection. Evidence suggests adenosine A1 receptor involvement, and possibly A3 receptor involvement in the rabbit. This study investigated the roles of these receptors in human preconditioning. Human A1- and A3-selective compounds were chosen based on K i values for inhibition of N 6-(4-amino-3-[125I]iodobenzyl)adenosine (125I-ABA) binding to stably expressed recombinant human A1 and A3 receptors. Cyclopentyladenosine (CPA), a 194-fold selective A1 agonist, and iodobenzylmethylcarboxamidoadenosine (IBMECA), a 10-fold selective A3 agonist were used alone and in combination with dipropylcyclopentylxanthine (DPCPX) a 62-fold selective A1 antagonist. Methods: Human atrial trabeculae were superfused with oxygenated Tyrode's solution. After stabilisation, muscles underwent one of 8 protocols ( n = 6 per group), followed by 90 min of simulated ischaemia and 120 min of reoxygenation. The experimental endpoint was recovery of contractile function, presented as percentage baseline function. Results: 5 nM CPA (52.2±3.1%), 30 nM IBMECA (49.7±3.8%) and preconditioning (55.3±2.5%) produced similar functional recoveries at 120 min of reoxygenation; significantly different to controls (27.7±1.0%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|